Policy changes Backwork has recorded, newest first. The most recent change on record is from October 24, 2026. Changes appear here after Backwork reviews and applies a refresh, so this page can trail the payers’ own sites.
Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
86,510 on record
| Recorded | Payer | Policy | Change |
|---|---|---|---|
| May 17, 2026 | BlueCross BlueShield of Tennessee | Ravulizumab-cwvz (Ultomiris) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Ranibizumab (Susvimo) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Ranibizumab (Lucentis, Byooviz; Cimerli) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Radiotherapy for Prostate Cancer | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Radiofrequency Tissue Volume Reduction (RFTVR) for the Treatment of Upper Airway Obstruction | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Radioembolization for Primary Tumors and Metastatic Tumors to the Liver | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Tofersen (Qalsody) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Treprostinil injection (Remodulin); Treprostinil | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Sipuleucel-T (Provenge) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Proton Beam Therapy | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Protein Profiling Assays for Breast Cancer Prognosis | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Prostate Specific Antigen (PSA) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Prademagene Zamikeracel (Zevaskyn) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Pozelimab-bbfg (Veopoz) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Positron Emission Tomography (PET) for Cardiac Applications | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Polatuzumab Vedotin-piiq (Polivy) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Plasminogen, human-tvmh (Ryplazim) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Plasma Exchange | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Photodynamic Therapy (PDT) for the Treatment of Certain Cancers | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Pharmacogenetic Testing for Pain Management | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Pertuzumab, Trastuzumab and Hyaluronidase-zzxf (Phesgo) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Pertuzumab (Perjeta); Pertuzumab-dpzb (Poherdy) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Peripheral Subcutaneous Field Stimulation for the Treatment of Pain | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Percutaneous Sacroplasty | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Percutaneous Arteriovenous Fistula (pAVF) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Treatment for Sexual Dysfunction in Males: Non-Pharmacologic | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Pemetrexed (Alimta; Pemfexy, Pemetrexed, Pemrydi RTU, Axtle) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Pegcetacoplan (Syfovre) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Sodium Thiosulfate (Pedmark) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Pasireotide (Signifor LAR) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Zopapogene Imadenovec-drba (Papzimeos) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Panitumumab (Vectibix) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Palivizumab (Synagis) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Lumasiran (Oxlumo) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Osteochondral Autografting | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Piezoelectric Sensor Analysis and Oscillating Force Delivered Vertebral Adjustment in the Evaluation and Treatment of the Spinal Column | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Orthopedic Applications of Stem Cell Therapy | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Orthognathic Surgery | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Oral Negative Pressure Therapy Devices for The Treatment of Sleep Apnea | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Orthoptic Training for the Treatment of Vision or Learning Disabilities | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Ophthalmologic Techniques for the Evaluation of Glaucoma | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Patisiran Lipid Complex (Onpattro) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Pegaspargase (Oncaspar) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Onasemnogene Abeparvovec-xioi (Zolgensma) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | OnabotulinumtoxinA (Botox) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Omalizumab Products: Omalizumab (Xolair); Omalizumab-igec (Omlyclo) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Olipudase Alfa-rpcp (Xenpozyme) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Octreotide Suspension (Sandostatin LAR Depot), Octreotide Acetate for Injectable Suspension | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Pegfilgrastim (Neulasta); Pegfilgrastim-jmdb (Fulphila); Pegfilgrastim--pbbk (Fylnetra); Pegfilgrastim- apgf (Nyvepria); Pegfilgrastim-fpgk (Stimufed); Pegfilgrastim-cbqv (Udenyca); Pegfilgrastim-bmez (Ziextenzo) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Nutritional Treatment of Inborn Errors of Metabolism | Criteria changed |